Strongbridge Biopharma is a global biopharmaceutical company that specializes in developing and commercializing therapies for rare diseases that are largely unmet, focusing on endocrine and neuromuscular diseases. Its commercial portfolio includes RECORLEV, a cortisol synthesis inhibitor, currently being studied for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being researched for the treatment of acromegaly, both of which have orphan drug designation from the FDA and the European Medicines Agency. The company's rare neuromuscular franchise offers KEVEYIS, the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, which has orphan drug exclusivity in the US.